It has been demonstrated that overexpressed ACE2 may inhibit cell growth and vascular endothelial growth factor production in lung cancer (Cheng et al., 2016), breast cancer (Yu et al., 2016), colon cancer (Bernardi et al., 2012), and pancreatic cancer (Zhou et al., 2011). Here, VEGFA is linked to lung cancer.